AACR Abstract 5583/15 Peg-ADA2 for CLL is HALO's 1st venture into CLL - Roche's territory- challenged by TGTX - Halo has targeted only solid cancer as a primary target till now. If this program pans out - even more of a reason for Roche to buy HALO. HALO also has a partnered trial w ADRO's LADD @AACR potentiaiong T cell I/O.